Post ISTH & ASH Headlines 2019

TRANSFUSION MEDICINE

Abstracts selected by Dr Andrew Charlton (Newcastle)

 Abstract 527
A Feasibility Randomized Trial of Red Cell Transfusion Thresholds in Myelodysplasia
Abstract (PDF)

 

Abstract 1
The Medalist Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions
Abstract (PDF)

 

Abstract 163
The Believe Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept in Adult Beta-Thalassemia Patients Who Require Regular Red Blood Cell (RBC) Transfusions
Abstract (PDF)

 

Abstract 463
Imetelstat Treatment Leads to Durable Transfusion Independence (TI) in RBC Transfusion-Dependent (TD), Non-Del(5q) Lower Risk MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Who Are Lenalidomide (LEN) and HMA Naive
Abstract (PDF)

 

Abstract 1826
Red Cell Alloimmunisation Is Associated with Increased Red Cell Transfusion Requirements in Myelodysplastic Syndrome
Abstract (PDF)

 

Abstract 2545
Daratumumab for Delayed Red Cell Engraftment after Hematopoietic Stem Cell Transplant
Abstract (PDF)

 

Abstract 415
Red Blood Transfusion Does Not Increase Risk for Venous or Arterial Thrombosis
Abstract (PDF)

 

Abstract 3821
Restrictive Versus Liberal Red Blood Cell Transfusion for Cardiac Surgery: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Abstract (PDF)

 

Abstract 2551
Red Blood Cell Allo-Antibodies after Allogeneic Hematopoietic Stem Cell Transplantation
Abstract (PDF)

 

Abstract 4717
Fetal-Neonatal Alloimmune Thrombocytopenia (FNAIT): Guidance to Reduce the Risk of Intracranial Bleeding

Abstract (PDF)